Over 25,000 of TheraCell's licensed demineralized bone fiber products have been delivered by its licensee partners, to date. These partners have notched steady double-digit quarter over quarter growth, now representing an annual end customer sales rate approaching $30 million.
Licensees of the base fiber technology include AlloSource, which produces and markets AlloFuse® Cortical Fibers and AlloFuse® Fiber Boats; TheraCell also produces private label products to be marketed by other orthopedic companies.
The full offering of procedure-specific fiber grafts is available in the U.S. directly through TheraCell, and will soon be available in Australia and New Zealand.
While the grafts distributed to date by TheraCell's licensees consist only of the original base fiber products, TheraCell has also launched an expanded portfolio of unique TheraFuze DBF® graft forms, including the DBF Fiber Anchor™ for immediate enhanced screw fixation, DBF Fiber Bullets™ for delivery through a cannula in MIS cases, the DBF Fiber Wrap™ and the DBF Fiber Bag™ for graft containment, and a 3-level DBF Fiber Boat™.
"The success our licensees are having is clear validation of our DBF technology. It provides a solid foundation as we continue to develop advanced bone graft solutions to facilitate surgical procedures." - Nelson Scarborough, Ph.D., CSO and co-inventor of TheraCell's DBF Bone Textile™ technology platform